Navigation Links
ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver

- Multi-Center Study in Skin Graft Donor Site Patients -

ADDISON, Texas, Oct. 21 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) today announced that it has commenced a clinical study to evaluate patients with graft donor sites treated with Altrazeal(TM) Silver compared with a market leading silver containing carboxymethylcellulose dressing. The study will be conducted at four clinical sites with 40 evaluable patients being enrolled. The first study site has been initiated and the Company plans to initiate additional sites within the next 30-days.

Each patient will have two skin graft donor sites, with Altrazeal(TM) Silver being applied to one site and the competitive dressing being applied to the other site. The primary study objective is to evaluate wound healing. Secondary study objectives include evaluating the incidence of wound infection, number of dressing changes, patient pain and provider and patient satisfaction.

This study is designed to support the marketing of Altrazeal(TM) Silver and provide the necessary clinical data to apply for a CE mark which will enable Altrazeal(TM) Silver to be marketed in Europe and Canada.

Commenting on the clinical study, Renaat Van Den Hooff, Executive Vice President of Operations stated, "Silver containing dressings are used extensively in the skin graft donor site indication to protect against infection. Preliminary data that has been generated in skin graft donor sites with Altrazeal(TM) is very positive, indicating that both patient comfort and pain are improved with Altrazeal(TM). With the use of silver containing dressings increasing in both chronic wounds and burns, this product line extension is an important component of our wound care franchise."

Silver has broad-spectrum antimicrobial properties which is ideal for use in preventing and treating infected wounds and wounds at risk of infection. Reducing bacteria burden in the wounds has been shown to improve healing. In preclinical studies, using a porcine wound healing model, Altrazeal(TM) silver showed superior healing rates compared to competitive silver dressings.

The company strategy is to develop a range of Altrazeal(TM) products incorporating active compounds for the treatment of the various phases of wound healing, infection, inflammation, debridement, maturation and closure. Altrazeal(TM) Silver will be the first product to demonstrate execution of this strategy (by implementing this strategy we believe that we will be delivering the products necessary to significantly improve wound healing).

About ULURU Inc.:

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Nanoflex(TM) Aggregate technology. For further information about ULURU Inc., please visit our website at

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the response to the product from patients, the ability to use the product for chronic wounds, the product accelerates healing and decreases pain, decreases dressing changes and reduction in wound management nursing time. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007, Quarterly Report on Form 10-Q for the quarter ended June 30, 2008 and other reports filed by us with the Securities and Exchange Commission.

Contact: Company Media Contact:

Kerry P. Gray Stephen Zoegall, Ph.D.

President & CEO Berry & Co. Public Relations

Terry K. Wallberg (212) 253-8881

Vice President & CFO

(214) 905-5145

Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
2. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
3. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
4. Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
5. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
6. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
7. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
8. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
9. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
10. In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices
11. Burcon announces GRAS status for Puratein(R) & Supertein(TM)
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Marker Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
(Date:11/25/2015)... 25, 2015  The American Academy of Pediatrics ... and the March of Dimes cheered today,s signature ... Infants Act of 2015 (S.799), which takes ... born exposed to drugs, such as opioids, and ... all three organizations have worked together leading advocacy ...
(Date:11/25/2015)...  ARKRAY USA , Inc., a ... demonstrating the accuracy of its blood glucose meter systems. ... Diabetes and Cardiovascular Disease in Los Angeles ... ® 01 meter and the Assure ® ... to accurately measure glucose levels in blood is essential ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... There is only one major question facing all law firms ... This question has not been an easy question to answer. Especially when the senior ... younger workforce don’t share the same discipline around working long hours. , In ...
(Date:11/27/2015)... ... , ... A team of Swiss doctors has released a report on mesothelioma ... posted the findings on the website. Click here to read the details now. ... patients who were treated with chemotherapy followed by EPP surgery. Among the 106 patients ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is ... Pro X. With ProSidebar: Fasion, video editors can easily add an informative sidebar ... minimalist title opener. Utilize presets featuring self-animating drop zones, lines, bars, and text ...
(Date:11/27/2015)... ... 27, 2015 , ... The moment you stop improving is ... fulfilling the needs of advisers and clients but going above and beyond to ... customer service. However, there's always room for improvement, which is why the entire ...
(Date:11/27/2015)... ... 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces his ... is one of Joplin's most famous and beautiful concert posters. The concert was held ... Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's stardom ...
Breaking Medicine News(10 mins):